Trial Profile
A phase III study comparing carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L CBDCA/PEM vs DOC Phase III)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2022
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CBDCA/PEM-vs-DOC-Phase III
- 30 Aug 2022 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 21 Feb 2017 Status changed from recruiting to active, no longer recruiting.